(Q42940352)

English

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

scientific article published on 9 August 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 November 2017

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial (English)

1 reference

Europe PubMed Central

11 November 2017

phase II clinical trial

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Lorenzo Fornaro

4

1 reference

Europe PubMed Central

11 November 2017

Gabriella Fontanini

12

1 reference

Europe PubMed Central

11 November 2017

Fotios Loupakis

object named as

Fotios Loupakis

2

0 references

Chiara Cremolini

object named as

Chiara Cremolini

5

0 references

Alfredo Falcone

object named as

Alfredo Falcone

16

0 references

author name string

Gianluca Masi

1

1 reference

Europe PubMed Central

11 November 2017

Lisa Salvatore

3

1 reference

Europe PubMed Central

11 November 2017

Samanta Cupini

6

1 reference

Europe PubMed Central

11 November 2017

Andrea Ciarlo

7

1 reference

Europe PubMed Central

11 November 2017

Francesca Del Monte

8

1 reference

Europe PubMed Central

11 November 2017

Enrico Cortesi

9

1 reference

Europe PubMed Central

11 November 2017

Domenico Amoroso

10

1 reference

Europe PubMed Central

11 November 2017

Cristina Granetto

11

1 reference

Europe PubMed Central

11 November 2017

Elisa Sensi

13

1 reference

Europe PubMed Central

11 November 2017

Cristiana Lupi

14

1 reference

Europe PubMed Central

11 November 2017

Michele Andreuccetti

15

1 reference

Europe PubMed Central

11 November 2017

publication date

9 August 2010

1 reference

Europe PubMed Central

11 November 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

11 November 2017

11

1 reference

Europe PubMed Central

11 November 2017

845-852

1 reference

Europe PubMed Central

11 November 2017

9

1 reference

Europe PubMed Central

11 November 2017

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimates of cancer incidence and mortality in Europe in 2008.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

One-sample multiple testing procedure for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(10)70175-3

1 reference

Europe PubMed Central

11 November 2017

release_darmc4w6mfciveymmte3qh2w3y

1 reference

https://api.fatcat.wiki/v0/release/darmc4w6mfciveymmte3qh2w3y

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

11 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42940352&oldid=1974099772"